Company Research Report: Sonavex, Inc.

Company Overview

Name: Sonavex, Inc.

Mission: Sonavex is dedicated to empowering clinicians to provide superior care and deliver savings to the healthcare system through their novel and automated ultrasound technology which provides actionable data to inform treatment decisions.

Founded By: Devin O’Brien-Coon, MD, MSE, and Jerry Prince, PhD.

Key People:

• David Narrow - Chief Executive Officer

• John Rappe - Chief Business Officer

• Alex Yevzlin, MD - Chief Medical Officer

• Florin Neacsu - Vice President of Engineering & Operations

• Katy Feeny - Director of Clinical Affairs

• Xin “Ben” Kang, PhD - Vice President of Research & Development

Board of Directors:

• Bill Niland

• Bob Hallenbeck

• Michael Hennessy, Jr.

• David Narrow

• Devin O’Brien-Coon, MD, MSE

• Jerry Prince, PhD

Headquarters: No information is available.

Number of Employees: No information is available.

Revenue: No information is available.

Company Known For: Sonavex is known for its specialized, groundbreaking EchoMark and EchoSure ultrasound technologies designed to collect clinical data for arteriovenous fistula evaluation.

Products

1. EchoMark

• Description: EchoMark is the first ultrasound marker designed for blood vessels. It is a highly echogenic and bioresorbable polymeric implant used for marking soft tissue sites in surgical patients.

• Key Features:

• Delivers vivid ultrasound images using a patented manufacturing technique.

• Fully bioresorbable, dissolves within 18-24 months.

• Unique 2D cross-section and geometric signature for different viewing angles.

2. EchoSure

• Description: EchoSure enables automatic detection of volumetric flow, diameter, and depth for arteriovenous fistula at the dialysis clinic to support maturation assessment.

• Key Features:

• Designed for operation by non-sonographer staff like dialysis techs and nurses.

• Demonstrated accuracy comparable or superior to standard duplex ultrasound techniques in studies.

• Provides quantitative data that informs early clinical decisions.

Recent Developments

Innovations and Awards:

• EchoMark and EchoSure were selected by TIME as one of the Best Inventions of 2024.

Financial & Collaborative Developments:

• Raised $15M in Series A-2 financing to support the development of novel ultrasound solutions.

• NIH awarded $2 million for conducting clinical trials and seeking regulatory clearance of EchoGuide technology.

Clinical Advancements:

• Published clinical data in the Journal of Vascular Access validating the performance of EchoMark and EchoSure.

• Announced successful clinical studies and initiated the MAFASA Randomized Controlled Trial.

Regulatory Progress:

• Received an AMA-issued CPT code for EchoSure technology.

Technical Improvements:

• Ongoing development and testing for new applications in vascular surgery and other areas supported by additional NIH grants.

Partnerships: No information is available.

Please note, some details such as headquarters location, employee number, and revenue were not available in the provided data. The available information focuses heavily on product offerings, technological advancements, and strategic financial developments.